Skip to content

Ashland ASH Life Sciences — Goodwill Gross

Similar metrics at other companies

Donaldson Company logo
DCILife Sciences Segment — Goodwill
$172.8M+2.2%
Revvity logo
RVTYLife Sciences — Goodwill
$4.75B+3.9%
Bio-Rad Laboratories logo
BIOLife Science — Goodwill, net
$448.7M+53.9%
Clarivate logo
CLVTLife Sciences & Healthcare — Goodwill
$256.1M
Bio-Rad Laboratories logo
BIOLife Science — Goodwill
$490.5M+47.2%
ExlService Holdings logo
EXLSHealthcare and Life Sciences — Goodwill
$189.57M0.0%

Other financials

Income statement

See full
Revenue$497.0M+7.3%
Gross profit$170.0M+28.8%
Operating income$43.0M+106%
Net income$16.0M+102%
EPS (diluted)$0.35+102%

Balance sheet

See full
Cash & equivalents$440.0M+113%
Total debt$1.5B-0.6%
Total equity$1.9B-1.0%
Total assets$4.6B-0.9%

Cash flow

See full
Operating cash flow$120.0M+4.3%
CapEx$20.0M0.0%
Free cash flow$100.0M+5.3%

Valuation

See full
Market cap$3.04B+35.8%
Enterprise value$4.08B+16.2%
P/E152×
P/S1.7×+0.5×

Profitability

See full
Gross margin31.5%+1.4pp
Operating margin4.1%
Net margin1.1%+0.5pp
FCF margin13.6%+9.7pp

Returns & leverage

See full
Return on equity1.1%+0.5pp
Debt / equity0.8×0.0×
Current ratio+0.4×

Where this comes from

Reported directly by Ashland in its filing.

Tagged under the XBRL concept us-gaap:GoodwillGross.

The official record: Ashland’s 10-Q, filed July 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ashland's life sciences — goodwill gross.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ashland's life sciences — goodwill gross?
Ashland (ASH) reported life sciences — goodwill gross of $841M in Q2 2026.
What does life sciences — goodwill gross mean?
This represents the total unadjusted value of goodwill recorded on the balance sheet for the Life Sciences segment, typically arising from historical business acquisitions. It reflects the premium paid over the fair value of net identifiable assets, representing intangible synergies and market position. It is a key component in assessing the segment's historical acquisition strategy and potential for future impairment risk.